BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating

Reuters2025-03-17

BUZZ-H.C. Wainwright starts coverage on Actuate <a href="https://laohu8.com/S/LENZ">Therapeutics</a> with 'buy' rating

** Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics ACTU.O with "buy" rating

** Brokerage sets PT at $20, representing more than 100% upside to the stock's last close

** In a mid-stage study, co's experimental therapy for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death

** Brokerage says the trial data for the therapy, elraglusib, "positions it as a frontrunner among competition" for pancreatic cancer treatments

** Brokerage is optimistic about ACTU because the pancreatic cancer market has a significant unmet need

** Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033

** ACTU has fallen 8.9% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520615542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-17 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520615542","market":"us","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage on Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> with 'buy' rating</title></head><body><p>** Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics <span>ACTU.O</span> with \"buy\" rating </p><p>** Brokerage sets PT at $20, representing more than 100% upside to the stock's last close</p><p><span>** In a mid-stage study, co's experimental therapy </span>for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death </p><p>** Brokerage says the trial data for the therapy, elraglusib, \"positions it as a frontrunner among competition\" <span>for pancreatic cancer treatments </span></p><p>** Brokerage is optimistic about ACTU because the pancreatic cancer market <span>has </span>a significant unmet need </p><p>** Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033</p><p>** ACTU has fallen 8.9% YTD</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-17 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage on Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> with 'buy' rating</title></head><body><p>** Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics <span>ACTU.O</span> with \"buy\" rating </p><p>** Brokerage sets PT at $20, representing more than 100% upside to the stock's last close</p><p><span>** In a mid-stage study, co's experimental therapy </span>for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death </p><p>** Brokerage says the trial data for the therapy, elraglusib, \"positions it as a frontrunner among competition\" <span>for pancreatic cancer treatments </span></p><p>** Brokerage is optimistic about ACTU because the pancreatic cancer market <span>has </span>a significant unmet need </p><p>** Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033</p><p>** ACTU has fallen 8.9% YTD</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLTE","symbol_name":"Belite Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL4N3Q00SZ:1","article_id":"2520615542","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520615542","pubTimestamp":1742211831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating** Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics ACTU.O with \"buy\" rating ** Brokerage sets PT at $20, representing more than 100% upside to the stock's last close** In a mid-stage study, co's experimental therapy for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death ** Brokerage says the trial data for the therapy, elraglusib, \"positions it as a frontrunner among competition\" for pancreatic cancer treatments ** Brokerage is optimistic about ACTU because the pancreatic cancer market has a significant unmet need ** Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033** ACTU has fallen 8.9% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BLTE":"Belite Bio, Inc.","ACTU":"Actuate Therapeutics Inc"},"translate_title":"巴斯-H.C。Wainwright开始对Actuate Therapeutics给予“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLTE":0.9,"ACTU":0.9},"content_text":"BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating** Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics ACTU.O with \"buy\" rating ** Brokerage sets PT at $20, representing more than 100% upside to the stock's last close** In a mid-stage study, co's experimental therapy for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death ** Brokerage says the trial data for the therapy, elraglusib, \"positions it as a frontrunner among competition\" for pancreatic cancer treatments ** Brokerage is optimistic about ACTU because the pancreatic cancer market has a significant unmet need ** Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033** ACTU has fallen 8.9% YTD (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520615542","isCrawlerRequest":true}